Modality
Nanobody
MOA
GLP-1ag
Target
BET
Pathway
NF-κB
MSGISTPNH
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Oct 2025
Phase 2Current
NCT08642385
2,748 pts·MS
2025-01→TBD·Active
NCT03293664
958 pts·GIST
2017-04→2025-10·Recruiting
3,706 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-155mo agoPh2 Data· GIST
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2025-10-15 · 5mo ago
GIST
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET |